A Shanghai company that started by helping stroke patients walk is now worth more than a billion dollars.
Its path to that valuation ran through hospital wards, not conference stages.
Fourier bet that rehabilitation robots and humanoids (人形机器人) could share the same muscles and motors — and investors bought the story.
Key takeaways
- Fourier Intelligence closed a Series E in early 2025 of about RMB 800 million (≈ US$113M / HK$880M) at a valuation later disclosed near RMB 8 billion (≈ US$1.13B / HK$8.8B).
- A later 2025 strategic investment from Runyang Technology of about RMB 300 million (≈ US$42M / HK$330M) kept the valuation around RMB 8 billion.
- Baidu Baike calls it the first unicorn in China's embodied intelligence (具身智能) field — a claim worth flagging, not just repeating.
- Unlike pure humanoid (人形机器人) startups, Fourier ships revenue-generating medical hardware today, which is the cushion behind the bet.
The round, in numbers
Fourier Intelligence (傅利叶智能), founded in Shanghai in 2015 by Gu Jie (顾捷), began in rehabilitation robotics — exoskeletons and therapy devices — before pivoting into general-purpose humanoids.
The verified financing picture:
- Series E, early 2025: roughly RMB 800 million (≈ US$113M / HK$880M), led by state-linked Guoxin Investment, alongside Pudong Venture Capital, Zhangjiang Venture Capital, Prosperity7 (Saudi Aramco's venture arm) and Junshan Capital.
- Valuation: about RMB 8 billion (≈ US$1.13B / HK$8.8B) post-money — above the US$1B line that defines a unicorn.
- Strategic round, 2025: Runyang Technology (润阳科技, 300920.SZ) committed about RMB 300 million (≈ US$42M / HK$330M) at a pre-money valuation near RMB 8 billion, per Baidu Baike and Phoenix Weekly reporting.
- Total raised to date: tracked by industry databases at roughly US$200M–290M across earlier rounds, including a 2022 Series D of about RMB 400 million led by SoftBank's Vision Fund.
The company's rehabilitation exoskeleton holds a leading domestic market share, with overseas revenue near 20% and deployments across 40-plus countries.
Why care robots are the anchor
Most humanoid (人形机器人) startups burn cash on a dream. Fourier's difference is a paying customer base that already exists: hospitals.
Its lower-limb exoskeletons and therapy robots generate real revenue and give the firm a "safety cushion," as one exchange-linked analyst quoted by Phoenix Weekly put it. That cash flow funds the riskier humanoid (人形机器人) program without starving the core business.
The humanoid (人形机器人) line — the GR series — is the growth story. The GR-1, unveiled in 2023, was among the first Chinese general-purpose humanoids to reach 量产 (mass production). The GR-3, shown in 2025, is pitched as a care and companion bot with 55 degrees of freedom and multimodal sensing.
The Meta wrinkle
In 2025, Fourier drew attention for a quiet partnership with Meta. Reporting by The Information, cited by Chinese outlets, said Meta used Fourier as the hardware builder for a humanoid prototype code-named "Max," with Meta's team embedded in Fourier's Shanghai factory.
The framing matters. Analysts described it as an ODM-style prototype build: Meta defined the brain and the scenario; Fourier built the body. That is a vote of confidence in Chinese robotics manufacturing — but also a warning that the higher-margin "AI brain" value may sit with the US partner, while the "engineering body" earns thinner margins.
The honest risks
Two cautions are worth stating plainly.
First, the unicorn label is a claim, not a verdict. Baidu Baike states Fourier is the first embodied intelligence (具身智能) unicorn in China; that is a reference-site assertion, not an audited ranking. The RMB 8 billion valuation, however, is well sourced.
Second, humanoid (人形机器人) revenue is still small. Gu Jie has said GR-series 2025 deliveries targeted only a few hundred units, with much of the near-term humanoid income coming from R&D, education and data collection rather than factory or elder-care work. At a 2026 Shanghai CPPCC session he noted that core components still account for more than 60% of a unit's cost — the kind of detail that keeps margins thin.
What readers can do now
- If you build or buy robots: benchmark Fourier's rehab hardware on a real clinical task before assuming a flashier humanoid (人形机器人) startup is more capable.
- If you follow listings: Fourier is reported to be preparing a STAR Market filing; a prospectus, not a rumor, is the proof.
- If you invest in China AI: separate the paying rehab business from the priced-for-the-future humanoid (人形机器人) bet — the first funds the second.
Honest limitations
Core facts — 2015 Shanghai founding by Gu Jie; Series E early 2025 ~RMB 800M (≈ US$113M / HK$880M) led by Prosperity7/Guoxin/Pudong VC at ~RMB 8B (≈ US$1.13B / HK$8.8B) valuation; 2025 Runyang New Material strategic ~RMB 300M (≈ US$42M / HK$330M) at ~RMB 8B pre-money; SoftBank Vision Fund-led 2022 Series D ~RMB 400M; leading domestic rehab exoskeleton share, ~20% overseas revenue, 40+ countries; GR-1 (2023) and GR-3 (2025, 55 DoF) humanoids — come from Baidu Baike, Phoenix Weekly / Tencent News (Nov 2026), and Sterling Charts / FOBI company profiles. The "first embodied intelligence unicorn" phrasing is Baidu Baike's claim, attributed as such. The Meta "Max" prototype and ODM framing come from The Information via Chinese media; treat the commercial structure as reported, not confirmed by either company. Gu Jie’s few-hundred-unit 2025 GR delivery target and >60% component-cost remark are from Phoenix Weekly and his 2026 Shanghai CPPCC comments. Currency uses fixed rates RMB 7.1 = US$1, RMB 1 = HK$1.1; conversions approximate. Round size and valuation are reported/disclosed figures, not an official audited statement beyond company and investor disclosures. Not investment advice. Current to 9 November 2026.